Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated at StockNews.com

Analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research note issued on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Price Performance

AKTX stock opened at $3.50 on Friday. The business has a fifty day moving average of $2.41 and a two-hundred day moving average of $2.23. Akari Therapeutics has a 52-week low of $1.08 and a 52-week high of $5.50.

Institutional Investors Weigh In On Akari Therapeutics

An institutional investor recently raised its position in Akari Therapeutics stock. Omnia Family Wealth LLC grew its position in Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 87,628 shares of the biopharmaceutical company’s stock after buying an additional 28,511 shares during the quarter. Omnia Family Wealth LLC owned 1.55% of Akari Therapeutics worth $273,000 as of its most recent filing with the Securities and Exchange Commission. 5.06% of the stock is currently owned by institutional investors.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.